Revamilast

Drug Profile

Revamilast

Alternative Names: GRC-4039

Latest Information Update: 29 Jun 2015

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Inflammation; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 30 Apr 2013 Glenmark Pharmaceuticals completes a phase II trial in Asthma in Czech Republic, India, Poland, Russia and United Kingdom (NCT01436890)
  • 31 Dec 2012 Glenmark Pharmaceuticals completes enrolment in its phase II trial for Asthma in UK, India, Poland, Russia and Czech Republic (NCT01436890)
  • 07 Aug 2012 Glenmark Pharmaceuticals completes enrolment in the phase IIb TERRA trial for Rheuamtoid arthritis in the UK, Poland, Philippines, India, and Sri Lanka (NCT01430507)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top